請更新您的瀏覽器

您使用的瀏覽器版本較舊,已不再受支援。建議您更新瀏覽器版本,以獲得最佳使用體驗。

Eng

HBM9378/WIN378, a Long-Acting, Fully Human Anti-TSLP Antibody, Enters Global Phase 2 POLARIS Trial for Asthma

PR Newswire (美通社)

更新於 07月23日12:59 • 發布於 07月23日12:36 • PR Newswire
  • Phase 2 POLARIS trial will evaluate the dosing, safety, and efficacy of HBM9378/WIN378 in patients with asthma, with an initial data readout expected in mid-2026

  • HBM9378/WIN378 has the potential to be the first-to-market long-acting anti-TSLP antibody with twice-yearly dosing for asthma

  • Extended dosing intervals could reduce treatment burden and improve outcomes for patients with advanced respiratory diseases

  • Global COPD clinical program planned to start in mid-2026

CAMBRIDGE, Mass. and ROTTERDAM, Netherlands and SHANGHAI, July 23, 2025 /PRNewswire/ -- Harbour BioMed (the "Company"; HKEX: 02142), a global biopharmaceutical company focused on the discovery and development of novel antibody therapeutics in immunology and oncology, today announced that its partner, Windward Bio AG ("Windward Bio"), has initiated the POLARIS clinical study, a global, randomized, double-blind, placebo-controlled Phase 2 study evaluating the dosing, safety, and efficacy of HBM9378/WIN378 in patients with asthma. Initial data are expected in mid-2026.

Asthma is a chronic respiratory condition affecting approximately 300 million people worldwide, with prevalence continuing to rise. Despite the availability of treatment options, many patients experience persistent symptoms, frequent exacerbations, and reduced quality of life. Current therapies - mainly inhaled corticosteroids (ICS) and bronchodilators - are inadequate for some patients, underscoring the urgent need for more effective, long-acting treatments that address the underlying disease mechanisms.

HBM9378/WIN378 is a potentially best-in-class, long-acting monoclonal antibody targeting thymic stromal lymphopoietin (TSLP), a well-validated cytokine that plays a key role in the development and progression of a wide array of immunological diseases, including asthma and chronic obstructive pulmonary disease (COPD). This molecule has fully human sequences, offering a lower risk of immunogenicity and improved bioavailability compared to other TSLP-targeting therapies. It has been engineered to achieve a half-life extension and a silenced effector function and is subcutaneously administered. In a Phase 1 trial, HBM9378/WIN378 demonstrated an extended half-life, showed a low incidence of antidrug antibodies, and was safe and well tolerated up to the highest tested dose.

"We are pleased to see HBM9378/WIN378 advancing rapidly into global clinical development," said Dr. Jingsong Wang, Founder, Chairman and CEO of Harbour BioMed. "This long-acting, fully human anti-TSLP antibody has demonstrated strong potential in previous preclinical and clinical studies. We believe it has the potential to address significant unmet needs for patients with asthma."

HBM9378/WIN378 (also known as SKB378) started as a co-development project jointly conducted by Harbour BioMed and Kelun-Biotech, with both parties equally sharing global rights. Earlier this year, Harbour BioMed and Kelun-Biotech entered into a strategic partnership with Windward Bio, granting Windward Bio an exclusive license to research, develop, manufacture, and commercialize this antibody globally, excluding Greater China and several Southeast and West Asian countries.

In addition to asthma, HBM9378/WIN378 is also being evaluated in clinical trials for COPD, another major respiratory condition. In November 2024, the Company submitted an Investigational New Drug (IND) application for HBM9378/WIN378 in COPD to the National Medical Products Administration (NMPA) of China, which was approved in January 2025. Additionally, Windward Bio plans to initiate global clinical trials in COPD in 2026. The continued progress of HBM9378/WIN378 in both asthma and COPD highlights the versatility and potential of this innovative therapy.

About Harbour BioMed
Harbour BioMed (HKEX: 02142) is a global biopharmaceutical company committed to the discovery and development of novel antibody therapeutics in immunology and oncology. The company is building a robust and differentiated pipeline through internal R&D capabilities, strategic global collaborations in co-discovery and co-development, and selective acquisitions.

Harbour BioMed's proprietary antibody technology platform, Harbour Mice®, generates fully human monoclonal antibodies in both the conventional two heavy and two light chain (H2L2) format and the heavy chain-only (HCAb) format. Building upon HCAb antibodies, the HCAb-based immune cell engagers (HBICE®) bispecific antibody technology enables tumor-killing effects that traditional combination therapies cannot achieve. Additionally, the HCAb-based bispecific immune cell antagonist (HBICATM) technology empowers the development of innovative biologics for immunological and inflammatory diseases. By integrating Harbour Mice®, HBICE®, and HBICATM with a single B-cell cloning platform, Harbour BioMed has built a highly efficient and distinctive antibody discovery engine for developing next-generation therapeutic antibodies. For more information, please visit .

About Windward Bio AG
Windward Bio is a clinical-stage biotechnology company with deep discovery, development and commercialization expertise committed to transforming the treatment of people living with advanced immunological conditions. Its lead program is WIN378, a potential best-in-disease, long-acting, anti-TSLP monoclonal antibody in Phase 2 for asthma. The company is planning additional clinical studies of WIN378 in COPD and other respiratory indications and is also building a pipeline of long-acting bi-specific antibodies targeting validated biology in respiratory and dermatological conditions. Windward Bio launched earlier this year with a $200M Series A led by top-tier investors.

查看原始文章

Quantum Solutions Announces Strategic Bitcoin Treasury Initiative with Initial Investment Backed by Integrated Asset Management (Asia) Limited

PR Newswire (美通社)

Global Dental Leaders to Convene in Shanghai for FDI World Dental Congress 2025

PR Newswire (美通社)

Bybit DeFi Report: RWA and DEXs Thrive Despite Cooling Market Activity

PR Newswire (美通社)
查看更多
Loading...
Loading...
Loading...
Loading...
Loading...
Loading...
Loading...
Loading...

最新內容

Update: China to allocate 90 billion yuan for nationwide childcare subsidies

XINHUA

Scorching heat fuels China's booming nighttime tourism

XINHUA

Update: Cambodia, Thailand reaffirm commitment to ceasefire agreement at trilateral meeting with China

XINHUA

China launches low Earth orbit satellite group

XINHUA

China, U.S. trade talks in-depth, candid, constructive, says China int'l trade representative

XINHUA

Study tour boom fuels China's countryside revival

XINHUA

The Philippines is troublemaker in South China Sea: defense ministry

XINHUA

Xinhua Commentary: Don't let peace in Gaza become a castle in the air

XINHUA

Xinhua News | CPC leadership holds symposium to seek advice on economic work

XINHUA

10 confirmed dead after bus goes missing in north China

XINHUA

CLO Unveils the zFab Kit: a Revolutionary AI-Powered Fabric Digitization System

PR Newswire (美通社)

China's Gen-Zers seek ancient healing at TCM night markets

XINHUA

Emerald Clinical Trials Confirms CEO Transition and Continuity Plan

PR Newswire (美通社)

Dx&Vx Signs USD 220 Million Co-Development and License Agreement for mRNA Cancer Vaccine with U.S. Biotech Company

PR Newswire (美通社)

FlyOverChina | A glimpse of night market in north China's Zhengding

XINHUA

Chinese, Russian navies to hold joint exercise, maritime patrol

XINHUA

China announces 14-man roster for final FIBA Asia Cup preparations

XINHUA

China hopes certain countries not to be swayed by "Taiwan independence" forces: spokesperson

XINHUA

GLOBALink | FPV drone tour of picturesque Chengkan Village in E China

XINHUA

Chancay-Shanghai shipping route boosts China-Peru trade

XINHUA

Update: CPC leadership holds symposium to seek advice on economic work

XINHUA

Xinhua News | China to earmark 90 billion yuan for childcare subsidies

XINHUA

Chery Group rejoins Fortune Global 500; LEPAS debuts at Jakarta Auto Show with first overseas orders

PR Newswire (美通社)

State Grid Gansu Linxia Power Supply Company: Strong Grid to Support Local Revitalization and Development

PR Newswire (美通社)

aiMotive Signs License Agreement with Socionext for aiWare NPU IP to Power Next-Gen ADAS SoC

PR Newswire (美通社)

WWII bond lives on as U.S. students pay tribute to Flying Tiger rescued by Chinese people

XINHUA

Thailand EV Board Adjusts EV3, EV3.5 Terms to Promote Exports as Investment in EV Supply Chain Tops 137 Billion Baht

PR Newswire (美通社)

10 confirmed dead after bus goes missing in north China

XINHUA

AI visionaries converge in Shanghai to chart the future of innovation

PR Newswire (美通社)

Chinese scientists unveil new insights into glacier melting in Central Asia

XINHUA

Chinese FM spokesperson briefs on latest round of China-U.S. trade talks

XINHUA

MetaOptics Ltd Lodges Preliminary Offer Document for Catalist Listing on the SGX-ST

PR Newswire (美通社)

SuperX Unveils the All-New SuperX XN9160-B200 AI Server, Powered by NVIDIA Blackwell GPU -- Accelerating AI Innovation by 30x as Compared to H100 Series with Supercomputer-Class Performance

PR Newswire (美通社)

War-scarred hinterlands reborn as prosperous mountain retreats

XINHUA

Hikvision unleashes the power of large-scale AI in traffic management by introducing next-generation traffic cameras and servers

PR Newswire (美通社)

Technology Drives Creativity: Digital Domain Showcases R&D Achievements at WAIC 2025

PR Newswire (美通社)

5th China-Mongolia Expo to boost regional cooperation

XINHUA

GLOBALink | Global youth unite in China to honor history and advocate for peace

XINHUA

Barry Callebaut Inaugurates Third Chocolate Factory in Neemrana, India

PR Newswire (美通社)

(Hello Africa) Cameroon hails health cooperation with China for half a century

XINHUA